Selective requirement for Mediator MED23 in Ras-active lung cancer

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 41, 2012, Pages

  Yang, Xu ^a   Zhao, Meng ^a   Xia, Min ^a   Liu, Yuting ^b   Yan, Jun ^b   Ji, Hongbin ^a   Wang, Gang ^a  

^a INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^b Chinese Academy of Sciences   (China)

Author keywords

Oncogene addiction; Therapeutic target; Transcription cofactor

Indexed keywords

MEDIATOR COMPLEX; MEDIATOR COMPLEX 23; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; RAS PROTEIN; TRANSCRIPTION FACTOR ELK 1; TRANSCRIPTOME; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SURVIVAL; CELL CYCLE; CELL LINE; CELL PROLIFERATION; ENZYME ACTIVITY; FEMALE; FIBROBLAST; GENE ACTIVITY; GENE CONTROL; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CANCER; LUNG CARCINOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION; XENOGRAFT;

ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; EMBRYO, MAMMALIAN; ETS-DOMAIN PROTEIN ELK-1; FEMALE; FIBROBLASTS; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LUNG; LUNG NEOPLASMS; MEDIATOR COMPLEX; MICE; MICE, KNOCKOUT; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASES; RAS PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRANSPLANTATION, HETEROLOGOUS;

EID: 84867389307     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1204311109     Document Type: Article

References (55)

1. Jemal A, et al. (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225-249.
2. Wistuba II, Gazdar AF (2006) Lung cancer preneoplasia. Annu Rev Pathol 1:331-348.
3. Herbst RS, Heymach JV, Lippman SM (2008) Lung cancer. N Engl J Med 359:1367-1380.
4. Karnoub AE, Weinberg RA (2008) Ras oncogenes: Split personalities. Nat Rev Mol Cell Biol 9:517-531. (Pubitemid 351881844)
5. Schubbert S, Shannon K, Bollag G (2007) Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 7:295-308. (Pubitemid 46480970)
6. Konstantinopoulos PA, Karamouzis MV, Papavassiliou AG (2007) Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nat Rev Drug Discov 6:541-555. (Pubitemid 47019443)
7. Cox AD, Der CJ (2002) Ras family signaling: Therapeutic targeting. Cancer Biol Ther 1: 599-606.
8. Downward J (2003) Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3:11-22.
9. Riely GJ, Marks J, PaoW(2009) KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc 6:201-205.
10. Roberts PJ, Der CJ (2007) Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26:3291-3310. (Pubitemid 46763022)
11. Engelman JA, et al. (2008) Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 14:1351-1356.
12. Sebolt-Leopold JS, Herrera R (2004) Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 4:937-947. (Pubitemid 39626217)
13. Stadler WM (2005) Targeted agents for the treatment of advanced renal cell carcinoma. Cancer 104:2323-2333.
14. Kornberg RD (2005) Mediator and the mechanism of transcriptional activation. Trends Biochem Sci 30:235-239.
15. Taatjes DJ (2010) The human Mediator complex: A versatile, genome-wide regulator of transcription. Trends Biochem Sci 35:315-322.
16. Malik S, Roeder RG (2010) The metazoan Mediator co-activator complex as an integrative hub for transcriptional regulation. Nat Rev Genet 11:761-772.
17. Kang YK, Guermah M, Yuan CX, Roeder RG (2002) The TRAP/Mediator coactivator complex interacts directly with estrogen receptors alpha and beta through the TRAP220 subunit and directly enhances estrogen receptor function in vitro. Proc Natl Acad Sci USA 99:2642-2647. (Pubitemid 34240514)
18. Kato Y, Habas R, Katsuyama Y, Näär AM, He X (2002) A component of the ARC/Mediator complex required for TGF beta/Nodal signalling. Nature 418:641-646.
19. Kim S, Xu X, Hecht A, Boyer TG (2006) Mediator is a transducer of Wnt/beta-catenin signaling. J Biol Chem 281:14066-14075.
20. Stevens JL, et al. (2002) Transcription control by E1A and MAP kinase pathway via Sur2 mediator subunit. Science 296:755-758. (Pubitemid 34442008)
21. Wang G, et al. (2005) Mediator requirement for both recruitment and postrecruitment steps in transcription initiation. Mol Cell 17:683-694. (Pubitemid 40320918)
22. Singh N, Han M (1995) sur-2, a novel gene, functions late in the let-60 ras-mediated signaling pathway during Caenorhabditis elegans vulval induction. Genes Dev 9:2251-2265.
23. Scholl C, et al. (2009) Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 137:821-834.
24. Barbie DA, et al. (2009) Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462:108-112.
25. Ferbeyre G (2007) Barriers to Ras transformation. Nat Cell Biol 9:483-485.
26. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW (1997) Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88:593-602. (Pubitemid 27152402)
27. Kamijo T, et al. (1997) Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91:649-659. (Pubitemid 27513656)
28. Sage J, et al. (2000) Targeted disruption of the three Rb-related genes leads to loss of G(1) control and immortalization. Genes Dev 14:3037-3050.
29. Buchwalter G, Gross C, Wasylyk B (2004) Ets ternary complex transcription factors. Gene 324:1-14. (Pubitemid 38030321)
30. Wang W, et al. (2009) Mediator MED23 links insulin signaling to the adipogenesis transcription cascade. Dev Cell 16:764-771.
31. Cantin GT, Stevens JL, Berk AJ (2003) Activation domain-mediator interactions promote transcription preinitiation complex assembly on promoter DNA. Proc Natl Acad Sci USA 100:12003-12008. (Pubitemid 37271505)
32. Boros J, et al. (2009) Elucidation of the ELK1 target gene network reveals a role in the coordinate regulation of core components of the gene regulation machinery. Genome Res 19:1963-1973.
33. Vijayvargia R, May MS, Fondell JD (2007) A coregulatory role for the mediator complex in prostate cancer cell proliferation and gene expression. Cancer Res 67:4034-4041. (Pubitemid 46815048)
34. Land H, Parada LF, Weinberg RA (1983) Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 304:596-602. (Pubitemid 13035496)
35. Sun P, et al. (2007) PRAK is essential for ras-induced senescence and tumor suppression. Cell 128:295-308. (Pubitemid 46123511)
36. Ruley HE (1983) Adenovirus early region 1A enables viral and cellular transforming genes to transform primary cells in culture. Nature 304:602-606.
37. Bhattacharjee A, et al. (2001) Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 98:13790-13795. (Pubitemid 33115977)
38. Luo J, et al. (2009) A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137:835-848.
39. Darnell JE, Jr. (2002) Transcription factors as targets for cancer therapy. Nat Rev Cancer 2:740-749.
40. Konstantinopoulos PA, Papavassiliou AG (2011) Seeing the future of cancer-associated transcription factor drug targets. JAMA 305:2349-2350.
41. Selivanova G, Wiman KG (2007) Reactivation of mutant p53: Molecular mechanisms and therapeutic potential. Oncogene 26:2243-2254. (Pubitemid 46536645)
42. Richon VM, O'Brien JP (2002) Histone deacetylase inhibitors: A new class of potential therapeutic agents for cancer treatment. Clin Cancer Res 8:662-664. (Pubitemid 34742091)
43. Pelengaris S, Khan M, Evan GI (2002) Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell 109:321-334. (Pubitemid 34606875)
44. Verma UN, Surabhi RM, Schmaltieg A, Becerra C, Gaynor RB (2003) Small interfering RNAs directed against beta-catenin inhibit the in vitro and in vivo growth of colon cancer cells. Clin Cancer Res 9:1291-1300. (Pubitemid 36418379)
45. Navone NM (2010) P-TEFb joins the family of cdks in oncology, promotes cell growth of cancer cells. Cell Cycle 9:2935.
46. Spaeth JM, Kim NH, Boyer TG (2011) Mediator and human disease. Semin Cell Dev Biol 22:776-787.
47. Firestein R, et al. (2008) CDK8 is a colorectal cancer oncogene that regulates betacatenin activity. Nature 455:547-551.
48. Mäkinen N, et al. (2011) MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. Science 334:252-255.
49. Adjei AA, et al. (2008) Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 26:2139-2146.
50. Bollag G, et al. (2010) Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467:596-599.
51. Puzanov I, Burnett P, Flaherty KT (2011) Biological challenges of BRAF inhibitor therapy. Mol Oncol 5:116-123.
52. Little AS, et al. (2011) Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. Sci Signal 4:ra17.
53. Sharma SV, Settleman J (2007) Oncogene addiction: Setting the stage for molecularly targeted cancer therapy. Genes Dev 21:3214-3231. (Pubitemid 350277749)
54. Weinstein IB, Joe AK (2006) Mechanisms of disease: Oncogene addiction - a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol 3:448-457. (Pubitemid 44203817)
55. Weinstein IB, Joe A (2008) Oncogene addiction. Cancer Res 68:3077-3080, discussion 3080.